• Publications
  • Influence
ESC GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF ACUTE AND CHRONIC HEART FAILURE 2008
Authors/Task Force Members: Kenneth Dickstein (Chairperson) (Norway)*, Alain Cohen-Solal (France), Gerasimos Filippatos (Greece), John J.V. McMurray (UK), Piotr Ponikowski (Poland), Philip Alexander
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
TLDR
LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure and decreased the symptoms and physical limitations of heart failure.
[Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European
TLDR
Authors/Task Force Members: Alec Vahanian (Chairperson) (France)*, Ottavio Alfieri (Chair person)* (Italy), Felicita Andreotti ( Italy), Manuel J. Antunes (Portugal) and Jose Luis Zamorano (Spain).
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society
TLDR
Recent surveys of Guidelines and Expert Consensus Documents published in peer-reviewed journals between 1985 and 1998 have shown that methodological standards were not complied with in the vast majority of cases.
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
TLDR
Cedesartan has a moderate impact in preventing admissions for CHF among patients who have heart failure and LVEF higher than 40%.
Eplerenone in patients with systolic heart failure and mild symptoms.
TLDR
Eplerenone, as compared with placebo, reduced both the risk of death and therisk of hospitalization among patients with systolic heart failure and mild symptoms.
Person-Centered Care — Ready for Prime Time
TLDR
A few simple routines to facilitate and safeguard the transition to person-centered care are proposed that if conscientiously and systematically applied, will help to make PCC the focus and mainstay of care in long-term illness.
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
TLDR
Valsartan is as effective as captopril in patients who are at high risk for cardiovascular events after myocardial infarction and the combination of the two on mortality in this population of patients.
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
TLDR
The results support the importance of heart-rate reduction with ivabradine for improvement of clinical outcomes in heart failure and confirm the important role of heart rate in the pathophysiology of this disorder.
...
1
2
3
4
5
...